A5060971939- Influenza Virus Research Studies
- Respiratory viral infections research
- Vaccine Coverage and Hesitancy
- Virus-based gene therapy research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 epidemiological studies
- Plant Virus Research Studies
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Plant Pathogens and Resistance
- COVID-19 Pandemic Impacts
- COVID-19 Clinical Research Studies
- Bladder and Urothelial Cancer Treatments
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Immunodeficiency and Autoimmune Disorders
- Plant Disease Resistance and Genetics
- Oral microbiology and periodontitis research
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- Animal Disease Management and Epidemiology
- Plant and Fungal Interactions Research
- Tuberculosis Research and Epidemiology
- COVID-19 impact on air quality
- Diagnosis and treatment of tuberculosis
Semmelweis University
1978-2024
University of Szeged
2020
National Public Health and Medical Officer Service
2020
National Center for Epidemiology
2011-2018
Office of the Chief Scientist
2017
Monash Institute of Medical Research
2010
University of South Florida
1995
Florida College
1995
St. Joseph's Hospital
1994-1995
Saint Joseph's Hospital
1994
Results from a European multicentre case-control study reported by Marta Valenciano and colleagues suggest good protection the pandemic monovalent H1N1 vaccine against pH1N1 no effect of 2009–2010 seasonal influenza on H1N1.
Binary file ES_Abstracts_Final_ECDC.txt matches
Since the 2008/9 influenza season, I-MOVE multicentre case–control study measures vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE A(H3N2) within season. Using combined data from 2010/11 to 2014/15 we studied effects of time since vaccination on type/subtype-specific VE. We modelled by using restricted cubic spline, controlling for potential confounders (age, sex, onset,...
COVID-19 epidemic has been suppressed in Hungary due to timely non-pharmaceutical interventions, prompting a considerable reduction the number of contacts and transmission virus. This strategy was effective preventing growth reducing incidence low levels. In this report, we present first epidemiological statistical analysis early phase outbreak Hungary. Then, establish an age-structured compartmental model explore alternative post-lockdown scenarios. We incorporate various factors, such as...
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 season Europe. Among 5547 SARI ≥18 years, 2963 (53%) were vaccinated influenza. Overall VE A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% -4-39) A(H3N2) and 56% 22-75) B. During season, while hospitalisation B >55%, it ≤20% for A subtypes. While vaccination should be...
Human peripheral blood lymphocytes from healthy adults, cord lymphocytes, and lymphoblastoid cell lines were screened by hybridization for the presence of group C adenovirus DNA sequences. In 13 17 lymphocyte samples 1 10 samples, seven tested, results positive Group (adenovirus [Ad1], Ad2, Ad5, or Ad6). About to 2% carried 50 100 viral genome copies per cell, as estimated in situ hybridization. Infectious virus representing all members recovered, but cultivation antibody did not cure cells...
In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza.Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days symptom onset. We compared...
In October 2011, a cluster of four tick-borne encephalitis (TBE) cases was identified in Hungary. Initial investigations revealed possible link with consumption unpasteurised cow milk sold by farmer without authorisation. We performed cohort study including all regular customers the farmer. Overall, eleven (seven confirmed and suspected) were identified. Customers who had consumed farmer’s more than two-fold increased risk for being TBE case, although not at statistically significant level.
Binary file ES_Abstracts_Final_ECDC.txt matches
Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE symptomatic BA.1/BA.2 infection investigate potential biases. Methods This test-negative multicentre study tested care patients with acute respiratory symptoms for the BA.1/BA.2-dominant period. estimated PS among adults adolescents (PS only) all products combined Comirnaty alone,...
In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. 2013-2014, we undertook a multicentre case-control based on sentinel practitioner surveillance networks six European Union (EU) countries to measure 2013-2014 VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses...
Introduction We describe COVID-19 morbidity, mortality, case fatality and excess death in a country-wide study of municipalities Hungary, exploring the association with socioeconomic status. Methods The spatial distribution mortality was mapped using hierarchical Bayesian smoothed indirectly standardised ratios. Indirectly ratios were used to evaluate between deprivation outcome measures. looked separately at morbidity 10 districts highest lowest share Roma population. Results Compared...
Governments are increasingly looking to vaccination provide a path out of the COVID-19 pandemic. Hungary offers an example investigate whether social inequalities compromise what successful vaccine program can achieve. morbidity, mortality, and coverage were characterized by calculation indirectly standardized ratios in Hungarian population during third pandemic wave at level municipalities, classified into deprivation quintiles. Then, their association with socioeconomic was assessed using...
Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim We aimed to measure VE against PCR-confirmed SARS-CoV-2 patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 July 2022 (Omicron-dominant period). Methods In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. defined complete...
We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential...
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% CI: 2 43) among 65-79-year-olds and 13% -15 30) those ≥ 80 years. As the component has not changed for 2017/18, physicians public health experts should be aware that could low where viruses predominate.
Background During the 2015/16 influenza season in Europe, cocirculating viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from B/Yamagata component trivalent vaccine. Methods We used test‐negative design a multicentre case‐control study twelve European countries to measure vaccine effectiveness ( VE ) against medically attended influenza‐like illness ILI laboratory‐confirmed as influenza. General practitioners swabbed systematic sample of consulting patients random...
Background Results of previous influenza vaccination effects on current season vaccine effectiveness (VE) are inconsistent. Objectives To explore VE among population targeted for vaccination. Methods We used 2011/2012 to 2016/2017 I‐MOVE primary care multicentre test‐negative data. For each season, we compared adjusted (aVE) between individuals vaccinated and unvaccinated in season. Using both seasons as a reference, then aVE seasons, only, only. included 941, 2645 959 influenza‐like illness...
The capacity of freshly explanted human peripheral blood lymphocytes (PBL) to support the replication adenovirus type 2 (Ad2) was investigated. Unlike other types cells, PBL were found be highly nonpermissive. Ad2 adsorbed 30 40% both T and non-T cells. Virus uncoating very slow inefficient, resulting in a 40-fold reduction compared with HEp-2 On population basis, viral DNA synthesis reduced 460-fold infectious virus production 10(6)-fold. Only 0.35% produced centers, yielding 0.8 PFU per...
SUMMARY The structure of adenovirus chromatin in infected cells was studied by micrococcal nuclease digestion and hybridization with virus-specific probes. In the early phase infection (5 h) a significant proportion viral molecules organized like actively transcribed cellular chromatin. As expected for transcriptionally active population molecules, even at high multiplicity nucleosomal repeating pattern less distinct than transformed cell which contained corresponding but genomic region....
Influenza A(H3N2) viruses predominated in Europe 2016-17. In 2017-18 and A(H1N1)pdm09 co-circulated. The vaccine component was the same both seasons; while changed 2017-18. seasons, seed developed adaptations/alterations during propagation eggs, impacting antigenicity.
In Europe, annual influenza vaccination is recommended to elderly. From 2011 2014 and in 2015-16, we conducted a multicentre test negative case control study hospitals of 11 European countries measure vaccine effectiveness (IVE) against laboratory confirmed hospitalised among people aged ≥65years. We pooled four seasons data IVE by past exposures vaccination. swabbed patients admitted for clinical conditions related with onset severe acute respiratory infection ≤7days before admission. Cases...
Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS European multicentre study end-of-season data to evaluate whether definition affected IVE estimates.